Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage

"Tirzepatide, the active ingredient in Eli Lilly’s Zepbound and diabetes injection Mounjaro, likely won’t be eligible for those negotiations until the end of the decade."
 
So from $399 down to $349 for the starting doses compared to direct to patient and $449 down from $499 for all other doses for most people not covered on Medicare / Medicaid. $50 off is better than nothing, I guess… 🥴
 
https://www.fidelity.com/news/article/investment-news/202511061712BENZINGAFULLNGTH48706737
Under the new deal, Medicare and Medicaid will begin covering obesity medications, including GLP-1 drugs – short for glucagon-like peptide-1 receptor agonists– starting in April 2026.

Patients will see monthly out-of-pocket costs ranging from $50 to $350, depending on dosage and insurance coverage — a sharp reduction from the $1,000-plus price tags many currently face.

Eli Lilly CEO Says ‘Turning Point’ In Obesity Fight​

"This action today will really begin to change the arc of chronic disease in our country," Dave Ricks, CEO of Eli Lilly ( LLY ), said, adding that the reduced cost "opens up access for millions of Medicare beneficiaries."

He cited powerful results from Lilly's Zepbound (tirzepatide), noting its ability to reduce the progression from prediabetes to type 2 diabetes by 94% over three years and showing significant cardiovascular benefits in clinical trials.

Ricks also teased the arrival of Lilly's next-generation pill, orforglipron, a once-daily oral treatment that aims to improve patient convenience
 
Medicare will start covering obesity drugs for some patients for the first time starting mid-2026. Certain Medicare patients will pay a copay of $50 per month for all approved uses of injectable and oral GLP-1 drugs, including diabetes and obesity treatment. Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk, pending approvals, will be $149 per month for everyone getting them through Medicare, Medicaid or TrumpRx.

- Great news for those who will be eligible!

Starting doses of existing injections like Novo’s Wegovy and Lilly’s Zepbound will be $350 per month on TrumpRX, but will “trend down” to $245 per month over a two-year period.

Still too much for a starting dose. This makes me think that this will only drive more people to compound and grey when the people they know who are eligible for Medicare coverage start getting their meds.
 
Too little too late for me ... but I'm happy for anyone who it does end up helping. Most insurance companies follow the state guidelines and Ohio pretty much bans coverage for weight loss drugs. Not a single plan on the marketplace covers them. I know, I checked.
Do they allow it for diabetics?
 
Top Bottom